Chennai, July 15: The Hyderabad-based Bharat Biotech International Ltd launched the countri's first recombinant epidermal growth factor - REGEN-D in Chennai on Friday.

The therapeutic has been developed and manufactured by the company over five years at a cost of Rs 18 crores, Dr Krishna M. Ella, chairman and managing director, Bharat Biotech said here.

The company received the necessary approvals for REGEN-D recently, Dr Ella said, adding, it has licences for the treatment of diabetic foot ulcers, burns and skin grafts.

REGEN-D is the result of an unique public-private technology collaboration between Bharat Biotech and the Institute of Genomics and Integrated Biology or IGIB, New Delhi. IGIB is a CSIR institution.